Cellectar Biosciences Inc (CLRB)
2.385
-0.08
(-3.44%)
USD |
NASDAQ |
Jul 05, 16:00
2.385
0.00 (0.00%)
After-Hours: 16:25
Cellectar Biosciences SG&A Expense (TTM): 13.32M for March 31, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 13.32M |
December 31, 2023 | 10.75M |
September 30, 2023 | 8.106M |
June 30, 2023 | 8.441M |
March 31, 2023 | 9.392M |
December 31, 2022 | 9.594M |
September 30, 2022 | 9.161M |
June 30, 2022 | 8.608M |
March 31, 2022 | 7.072M |
December 31, 2021 | 6.545M |
September 30, 2021 | 6.434M |
June 30, 2021 | 5.778M |
March 31, 2021 | 5.534M |
December 31, 2020 | 5.150M |
September 30, 2020 | 4.935M |
June 30, 2020 | 4.970M |
March 31, 2020 | 5.204M |
December 31, 2019 | 5.183M |
September 30, 2019 | 5.145M |
June 30, 2019 | 4.977M |
March 31, 2019 | 4.768M |
December 31, 2018 | 4.776M |
September 30, 2018 | 4.592M |
June 30, 2018 | 4.651M |
March 31, 2018 | 4.509M |
Date | Value |
---|---|
December 31, 2017 | 4.135M |
September 30, 2017 | 4.355M |
June 30, 2017 | 4.366M |
March 31, 2017 | 4.693M |
December 31, 2016 | 4.699M |
September 30, 2016 | 4.291M |
June 30, 2016 | 3.963M |
March 31, 2016 | 3.413M |
December 31, 2015 | 3.395M |
September 30, 2015 | 3.451M |
June 30, 2015 | 3.419M |
March 31, 2015 | 3.561M |
December 31, 2014 | 3.705M |
September 30, 2014 | 4.255M |
June 30, 2014 | 4.296M |
March 31, 2014 | 4.410M |
December 31, 2013 | 4.445M |
September 30, 2013 | 3.976M |
June 30, 2013 | 3.933M |
March 31, 2013 | 3.756M |
December 31, 2012 | 3.632M |
September 30, 2012 | 3.560M |
June 30, 2012 | 3.665M |
March 31, 2012 | 3.565M |
December 31, 2011 | 2.699M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
4.935M
Minimum
Sep 2020
13.32M
Maximum
Mar 2024
7.333M
Average
6.545M
Median
Dec 2021
SG&A Expense (TTM) Benchmarks
Perspective Therapeutics Inc | 19.11M |
Eli Lilly and Co | 6.912B |
Actinium Pharmaceuticals Inc | 12.56M |
NovaBay Pharmaceuticals Inc | 12.53M |
Palatin Technologies Inc | 13.34M |